Pharvaris exec sells 30,000 shares after option

Available on EDGAR 09/14/2026 - 12:30 PM EDT Accepted by SEC EDGAR 09/14/2026 - 12:29 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) reports that executive Anne Lesage exercised options and sold shares on September 10, 2026 under a Rule 10b5-1 trading plan. She exercised rights to acquire 8,000 common shares at $8.05 per share and held 15,000 options of this grant afterward, expiring April 6, 2033.

In connection with the exercise, she acquired and immediately sold 30,000 common shares in a cashless transaction at a weighted average price of $38.3028 per share, with sale prices ranging from $38.00 to $38.90. The option began vesting April 6, 2024, with remaining shares vesting in equal monthly installments.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Lesage Anne

Role Chief Early Development

Sold 30,000 shs ($1.15M)

Approx. gross sale proceeds $1.15M

Approx. exercise cost $64K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F3	8,000	$0.00	$0.00
Exercise	Common Stock F1	30,000	$8.05	$242K
Sale	Common Stock F1, F2	30,000	$38.3028	$1.15M

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct); Common Stock — 56,450 shares (Direct)

Footnotes (3)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.00 to $38.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Options exercised: 8,000 shares Exercise price: $8.05 per share Shares sold: 30,000 shares +4 more

7 metrics

Options exercised 8,000 shares Options to buy Pharvaris common stock exercised on September 10, 2026

Exercise price $8.05 per share Price at which 8,000 Pharvaris options were exercised

Shares sold 30,000 shares Common shares sold on September 10, 2026 in a cashless transaction

Weighted average sale price $38.3028 per share Average price for 30,000 Pharvaris shares sold, with prices from $38.00 to $38.90

Remaining options from grant 15,000 options Directly held options from this award after the reported exercise

Option vesting start 25% on April 6, 2024 Initial vesting tranche for the reported Pharvaris option grant

Option expiration April 6, 2033 Expiration date for the reported Pharvaris option grant

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, cashless exercise transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan."

cashless exercise transaction financial

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PHVS report for Anne Lesage on September 10, 2026?

Anne Lesage exercised options to acquire 8,000 Pharvaris N.V. shares at $8.05 and sold 30,000 common shares in a cashless transaction at a weighted average price of $38.3028 per share, with prices ranging from $38.00 to $38.90.

Was the September 10, 2026 PHVS insider trading by Anne Lesage under a Rule 10b5-1 plan?

Yes. The option exercise and related sales were described as a scheduled exercise and sale under a Rule 10b5-1 trading plan, reducing the informational value of the timing of these transactions for assessing insider sentiment.

How many Pharvaris (PHVS) options does Anne Lesage retain after the reported transaction?

After exercising 8,000 options, the report states that 15,000 options from this grant remain held directly by Anne Lesage, with an expiration date of April 6, 2033 and continuing vesting in monthly installments after April 6, 2024.

What was the price range for the 30,000 PHVS shares sold by Anne Lesage?

The 30,000 Pharvaris common shares were sold at prices ranging from $38.00 to $38.90 per share, resulting in a weighted average sale price of $38.3028 per share, as disclosed in the transaction footnote.

What is the vesting schedule of Anne Lesage’s Pharvaris stock options reported here?

For this option grant, 25% vested on April 6, 2024, with the remaining shares vesting in 1/48 monthly installments thereafter, leading up to an expiration date of April 6, 2033, subject to the usual award terms.

Did the PHVS Form 4 show a net share sale by Anne Lesage?

Yes. The transactions include an option exercise and a cashless sale of 30,000 common shares, resulting in a net reported sell direction for these trades, even though the exercise itself increased her directly held option-based rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lesage Anne

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Early Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		M(1)		30,000	A	$8.05	86,450	D
Common Stock	09/10/2026		S(1)		30,000	D	$38.3028(2)	56,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.05	09/10/2026		M			8,000	(3)	04/06/2033	Common Stock	8,000	$0	15,000	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.00 to $38.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)